Nuvectis has transformed from a small early-stage oncology biotech into a high-risk, late-stage precision-medicine platform with asymmetric upside tied to NXP100, NXP200, and successful financing of the Haisco deal.
Overview
Nuvectis Pharma is a pre-revenue, clinical-stage biotech pursuing precision oncology and complement-mediated disease therapies through a capital-efficient virtual model. Its investment value is concentrated in four clinical assets: NXP100, NXP200, NXP900, and NXP800. The June 2026 Haisco licensing deal materially upgraded the pipeline by adding late-stage complement and BRAF programs with meaningful clinical validation. NXP100’s once-daily oral profile and superior PNH data versus Soliris, plus NXP200’s paradox-breaker BRAF mechanism, create substantial upside, but execution, financing, dilution, and regulatory risks remain central.